Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis

There have been significant improvements in therapeutic options for relapsed multiple myeloma (MM) over the past two decades, with many novel agents including proteasome inhibitors, immunomodulatory agents, and more recently monoclonal antibodies demonstrating efficacy in this setting. However, ther...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Russell Sterrett, Amarilis Figueiredo, Ranjeeta Mallick, Natasha Kekre, Harold Atkins, Arleigh McCurdy
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Relapsed myeloma Cyclophosphamide Lenalidomide Survival Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/855b6e849f604315b0e9b1d6256a2e6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:855b6e849f604315b0e9b1d6256a2e6b
record_format	dspace
spelling	oai:doaj.org-article:855b6e849f604315b0e9b1d6256a2e6b2021-11-04T04:37:11ZCyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis2531-137910.1016/j.htct.2020.07.007https://doaj.org/article/855b6e849f604315b0e9b1d6256a2e6b2021-10-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137920301279https://doaj.org/toc/2531-1379There have been significant improvements in therapeutic options for relapsed multiple myeloma (MM) over the past two decades, with many novel agents including proteasome inhibitors, immunomodulatory agents, and more recently monoclonal antibodies demonstrating efficacy in this setting. However, there is a paucity of real-world data comparing outcomes seen in patients treated with novel agents as opposed to older agents. We report a historical single center cohort of patients diagnosed with myeloma between the years 1991–2012 in order to explore possible differences in outcomes. A total of 139 patients who underwent stem cell transplantation were included in our study. In our study, 88 patients were treated with cyclophosphamide and steroids alone at relapse whereas 51 patients were treated with Len-Dex. In the multivariate analysis, TTNT was shorter for patients who received Cyclo compared to Len-Dex (HR = 1.74; 95% CI, 1.01–2.99; p = 0.04); however, we could not detect an overall survival benefit (HR = 1.20; 95% CI 0.63–2.29; p = 0.57). Adverse event rates were similar in the two groups. In this retrospective single center analysis, Len-Dex was associated with longer TTNT compared with Cyclo at first relapse following autoSCT in MM; however its effect on overall survival in this setting was less clear.Russell SterrettAmarilis FigueiredoRanjeeta MallickNatasha KekreHarold AtkinsArleigh McCurdyElsevierarticleRelapsed myelomaCyclophosphamideLenalidomideSurvivalDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss 4, Pp 437-442 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Relapsed myeloma Cyclophosphamide Lenalidomide Survival Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Relapsed myeloma Cyclophosphamide Lenalidomide Survival Diseases of the blood and blood-forming organs RC633-647.5 Russell Sterrett Amarilis Figueiredo Ranjeeta Mallick Natasha Kekre Harold Atkins Arleigh McCurdy Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
description	There have been significant improvements in therapeutic options for relapsed multiple myeloma (MM) over the past two decades, with many novel agents including proteasome inhibitors, immunomodulatory agents, and more recently monoclonal antibodies demonstrating efficacy in this setting. However, there is a paucity of real-world data comparing outcomes seen in patients treated with novel agents as opposed to older agents. We report a historical single center cohort of patients diagnosed with myeloma between the years 1991–2012 in order to explore possible differences in outcomes. A total of 139 patients who underwent stem cell transplantation were included in our study. In our study, 88 patients were treated with cyclophosphamide and steroids alone at relapse whereas 51 patients were treated with Len-Dex. In the multivariate analysis, TTNT was shorter for patients who received Cyclo compared to Len-Dex (HR = 1.74; 95% CI, 1.01–2.99; p = 0.04); however, we could not detect an overall survival benefit (HR = 1.20; 95% CI 0.63–2.29; p = 0.57). Adverse event rates were similar in the two groups. In this retrospective single center analysis, Len-Dex was associated with longer TTNT compared with Cyclo at first relapse following autoSCT in MM; however its effect on overall survival in this setting was less clear.
format	article
author	Russell Sterrett Amarilis Figueiredo Ranjeeta Mallick Natasha Kekre Harold Atkins Arleigh McCurdy
author_facet	Russell Sterrett Amarilis Figueiredo Ranjeeta Mallick Natasha Kekre Harold Atkins Arleigh McCurdy
author_sort	Russell Sterrett
title	Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
title_short	Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
title_full	Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
title_fullStr	Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
title_full_unstemmed	Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
title_sort	cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/855b6e849f604315b0e9b1d6256a2e6b
work_keys_str_mv	AT russellsterrett cyclophosphamideglucocorticoidsversuslenalidomidedexamethasoneastreatmentformultiplemyelomaatfirstrelapseafterautologousstemcelltransplantationaretrospectiveanalysis AT amarilisfigueiredo cyclophosphamideglucocorticoidsversuslenalidomidedexamethasoneastreatmentformultiplemyelomaatfirstrelapseafterautologousstemcelltransplantationaretrospectiveanalysis AT ranjeetamallick cyclophosphamideglucocorticoidsversuslenalidomidedexamethasoneastreatmentformultiplemyelomaatfirstrelapseafterautologousstemcelltransplantationaretrospectiveanalysis AT natashakekre cyclophosphamideglucocorticoidsversuslenalidomidedexamethasoneastreatmentformultiplemyelomaatfirstrelapseafterautologousstemcelltransplantationaretrospectiveanalysis AT haroldatkins cyclophosphamideglucocorticoidsversuslenalidomidedexamethasoneastreatmentformultiplemyelomaatfirstrelapseafterautologousstemcelltransplantationaretrospectiveanalysis AT arleighmccurdy cyclophosphamideglucocorticoidsversuslenalidomidedexamethasoneastreatmentformultiplemyelomaatfirstrelapseafterautologousstemcelltransplantationaretrospectiveanalysis
_version_	1718445285153177600

Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis

Ejemplares similares